Advanced Filters
noise

Wien, Austria Clinical Trials

A listing of Wien, Austria clinical trials actively recruiting patients volunteers.

Found 334 clinical trials
M Michael Leutner, Priv.Doz. Dr.med.univ.

The Effects of Dietary Supplements on Glycemic Control, Body Composition and Hepatic Fat Content in People With Prediabetes

This clinical study aims to explore the effects of 3 dietary supplements on metabolic parameters, liver fat content, and body composition in individuals with prediabetes. Prediabetes refers to a condition where blood sugar levels are higher than normal but not high enough for a diabetes diagnosis. The study will last …

40 - 80 years of age All Phase N/A
M Marika Rosner

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Polatuzumab, bendamustine and rituximab in patients with relapsed/ refractory mantle cell lymphoma

18 - 100 years of age All Phase 2
P Preston Long, PhD

The Mere-measurement Effect of Patient-reported Outcomes

The use of patient-reported outcome (PROs) have become increasingly commonplace across many healthcare settings over the past two decades. The value of PROs is now acknowledged by healthcare providers and patients alike. However, to date, little is known about the best practices for formulating PRO measures (PROMS), but even more …

18 years of age All Phase N/A
V Vincenz Scharner, Dr. med.

Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support

A three-arm randomized controlled non-inferiority pilot study comparing anticoagulation strategies using unfractionated heparin, argatroban and enoxaparin for extracorporeal membrane oxygenation support conducted as an investigator-initiated, prospective, parallel group, open-label, active comparator controlled, single center, phase IV study to evaluate the non-inferiority of enoxaparin or argatroban for anticoagulation during ECMO therapy …

18 years of age All Phase 4
R Rupert Lanzenberger, Assoc. Prof. PD MD

Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People

Major depressive disorder was shown to be associated with pathological alterations within neurotransmitter systems of the brain. Based on earlier study results, it is assumed that the neurotransmitter dopamine is relevant for several symptoms of depression, e.g., loss of interest or pleasure and lack of motivation. Thus, it is assumed …

18 - 65 years of age All Phase 4
T Thomas Staudinger, MD

Hemodynamic Monitoring and Fluid Responsiveness in Venovenous Extracorporeal Membrane Oxygenation (VV ECMO) - "HemodynamECMOnitoring-VV Study"

In extracorporeal membrane oxygenation (ECMO), blood is drawn out of the body via tubes, oxygenated in an artificial lung; and then pumped back into the blood vessels. This allows the supply of oxygen-rich blood to the organs (brain, heart, lungs, kidneys, liver, intestines, etc.) to be maintained. Continuous monitoring of …

18 - 75 years of age All Phase N/A
S Stefan Ulbing, Dr.med.univ.

Effect of Music on Patient Comfort

Perioperative anxiety remains a prevalent and significant concern for patients undergoing surgery, with substantial impacts on postoperative pain perception, patient satisfaction and recovery. Historically, anxiolytics (e.g. benzodiazepines) were often routinely administered preoperatively in this context, accepting the potential negative side effects of pharmacotherapy. In recent literature, there is an increasing …

18 - 70 years of age All Phase N/A

Meningococcal B Vaccine in Patients with Asplenia

Patients without a spleen (asplenia) experience an increased risk for septicaemia from encapsulated bacteria, which is associated with a high mortality rate. Meningococcal bacteria can cause such infections and serogroup B is the dominant meningococcal subtype in Europe. Therefore, vaccination for risk populations like patients without a spleen is a …

18 - 60 years of age All Phase 2
M Martin Kronschläger, PhD

Visual Performance of an Extended Depth of Focus IOL in an Emmetropic or Monovision Modality

Comparison of the visual performance of a refractive extended depth of focus intraocular lens in an emmetropic or monovision modality

21 - 105 years of age All Phase N/A

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation

The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

18 years of age All Phase 2

Simplify language using AI